{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:45:39Z","timestamp":1792442739164,"version":"4.5.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,9]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Autoimmune inner ear disease typically presents with bilateral hearing loss that progresses over weeks or months though its mechanisms are unknown. Corticosteroids are the first-line treatment, but their responses are variable and relapses are frequent. Thus, many experts have sought to replace corticosteroids with immunosuppressive agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 35-year-old woman experienced a progressive hearing impairment, initially on the left side and later becoming bilateral. Her response to corticosteroid monotherapy was temporary, and there have been two relapse episodes over several months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Autoimmune inner ear disease was considered due to evidence of autoimmunity combined with a clinical course of bilateral and recurrent sensorineural hearing loss and a partial response to corticosteroid therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received a 3-day mini-pulse of methylprednisolone at 250\u2009mg\/d, followed by 12\u2009mg\/d maintenance, and concurrently began an azathioprine regimen gradually increasing to 100\u2009mg\/day as a corticosteroid-sparing agent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Three weeks after immunosuppressive therapy, hearing and pure-tone audiometry improved, and after 7 weeks, methylprednisolone was tapered to 8\u2009mg\/d. The dosage was further reduced by adding methotrexate at 7.5\u2009mg\/week, resulting in a reduction to 4\u2009mg\/d as maintenance therapy after 4 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>For patients who are unresponsive to corticosteroids or experience difficulty tolerating them, a combination therapy of methotrexate and azathioprine is recommended as a viable alternative as this regimen is well-tolerated and yields positive outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033889","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:23:25Z","timestamp":1686320605000},"page":"e33889","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review"],"prefix":"10.1097","volume":"102","author":[{"given":"Kuan-Hsuan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Education, Shin Kong Wu Ho Su Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Ching","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Education, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Der","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Department of Otolaryngology Head and Neck Surgery, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chang","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan"},{"name":"Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.0307-7772.2003.00738.x","article-title":"Autoimmune sensorineural hearing loss.","volume":"28","author":"Mathews","year":"2003","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/000348947908800501","article-title":"Autoimmune sensorineural hearing loss.","volume":"88","author":"McCabe","year":"1979","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/lio2.508","article-title":"Autoimmune inner ear disease: a systematic review of management.","volume":"5","author":"Nathaniel","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2058738418808680","DOI":"10.1177\/2058738418808680","article-title":"Autoimmune inner ear disease (AIED): a diagnostic challenge.","volume":"32","author":"Ciorba","year":"2018","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/lio2.28","article-title":"AAO: Autoimmune and autoinflammatory (disease) in otology: what is new in immune-mediated hearing loss.","volume":"1","author":"Vambutas","year":"2016","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/ket009","article-title":"Autoimmune sensorineural hearing loss: the otology-rheumatology interface.","volume":"52","author":"Mijovic","year":"2013","journal-title":"Rheumatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00405-008-0801-y","article-title":"The diagnosis of autoimmune inner ear disease: evidence and critical pitfalls.","volume":"266","author":"Bovo","year":"2009","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1080\/00016480600606723","article-title":"Immune-mediated inner ear disease.","volume":"126","author":"Bovo","year":"2006","journal-title":"Acta Otolaryngologica"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.otorri.2017.08.008","article-title":"Immune-mediated inner ear disease: diagnostic and therapeutic approaches.","volume":"70","author":"Pen\u00eada","year":"2019","journal-title":"Acta Otorrinolaringol Esp"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2217\/imt.09.12","article-title":"Immunosuppressive therapy for autoimmune inner ear disease.","volume":"1","author":"Buniel","year":"2009","journal-title":"Immunotherapy"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/000164802320396402","article-title":"Autoimmune sensorineural hearing loss improved by tumor necrosis factor-a blockade: a case report.","volume":"122","author":"Staecker","year":"2002","journal-title":"Acta Otolaryngol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00405-019-05681-5","article-title":"Demystifying autoimmune inner ear disease.","volume":"276","author":"Das","year":"2019","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1096\/fasebj.10.14.9002556","article-title":"Myelin protein Po as a potential autoantigen in autoimmune inner ear disease.","volume":"10","author":"Cao","year":"1996","journal-title":"FASEB J"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00129492-200109000-00009","article-title":"COCH5B2 is a target antigen of anti-inner ear antibodies in autoimmune inner ear diseases.","volume":"22","author":"Boulassel","year":"2001","journal-title":"Otol Neurotol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00019052-200102000-00006","article-title":"Autoimmune inner ear disorders.","volume":"14","author":"Ryan","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/000164802320396402","article-title":"Autoimmune sensorineural hearing loss improved by tumor necrosis factor-a blockade: a case report.","volume":"122","author":"Staecker","year":"2002","journal-title":"Acta Otolaryngol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/01.MLG.0000158666.15447.37","article-title":"Antiphospholipid inner ear syndrome.","volume":"115","author":"Mouadeb","year":"2005","journal-title":"Laryngoscope"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/coa.12432","article-title":"Current understanding of the pathogenesis of autoimmune inner ear disease: a review.","volume":"40","author":"Goodall","year":"2015","journal-title":"Clin Otolaryngol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1749-6632.1997.tb51895.x","article-title":"The endolymphatic sac as the immunocompetent organ of the inner ear.","volume":"830","author":"Barbara","year":"1997","journal-title":"Ann N Y Acad Sci"},{"key":"R20-20250504","article-title":"The role of autoimmunity in the pathogenesis of sudden sensorineural hearing loss.","volume":"7691473","author":"Li","year":"2018","journal-title":"Neural Plast"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3109\/00016488709107271","article-title":"The role of the endolymphatic sac in inner ear immunity.","volume":"103","author":"Tomiyama","year":"1987","journal-title":"Acta Otolaryngol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1288\/00005537-198810000-00018","article-title":"Analysis of immunocompetent cells following inner ear stimulation.","volume":"98","author":"Takahashi","year":"1988","journal-title":"Laryngoscope"},{"key":"R23-20250504","first-page":"530","article-title":"Breakdown of stria vascularis bloodlabyrinth barrier in C3H\/lpr autoimmune disease mice.","volume":"117","author":"Lin","year":"1997","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/lio2.508","article-title":"Autoimmune inner ear disease: a systematic review of management.","volume":"5","author":"Breslin","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.wjorl.2015.11.001","article-title":"Assessment of complications due to intratympanic injections.","volume":"2","author":"Liu","year":"2016","journal-title":"World J Otorhinolaryngol Neck Surg"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00405-006-0096-9","article-title":"Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: a physiopathologic approach.","volume":"263","author":"Garc\u00eda-Berrocal","year":"2006","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1044\/1059-0889(2012\/12-0040)","article-title":"Autoimmune inner ear disease preliminary case report: audiometric findings following steroid treatments.","volume":"22","author":"Harris","year":"2013","journal-title":"Am J Audiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005537-199907001-00001","article-title":"Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.","volume":"109","author":"Parnes","year":"1999","journal-title":"Laryngoscope"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.semarthrit.2004.07.001","article-title":"Immune-mediated inner ear disease: 10-year experience.","volume":"34","author":"Broughton","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/014556130108001110","article-title":"Autoimmune inner ear disease: steroid and cytotoxic drug therapy.","volume":"80","author":"Lasak","year":"2001","journal-title":"Ear Nose Throat J"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.amjoto.2019.102310","article-title":"An update on autoimmune inner ear disease: a systematic review of pharmacotherapy.","volume":"41","author":"David","year":"2020","journal-title":"Am J Otolaryngol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.290.14.1875","article-title":"Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.","volume":"290","author":"Harris","year":"2003","journal-title":"JAMA"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/1529-0131(200104)45:2<146::AID-ANR167>3.0.CO;2-I","article-title":"Open trial of methotrexate as treatment for autoimmune hearing loss.","volume":"45","author":"Matteson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R35-20250504","first-page":"1037","article-title":"Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients.","volume":"28","author":"Salley","year":"2001","journal-title":"J Rheumatol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1288\/00005537-199408000-00004","article-title":"Methotrexate therapy for autoimmune hearing loss: a preliminary report.","volume":"104","author":"Sismanis","year":"1994","journal-title":"Laryngoscop"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/030006059302100404","article-title":"Azathioprine in combination with steroids in the treatment of autoimmune inner-ear disease.","volume":"21","author":"Saracaydin","year":"1993","journal-title":"J Int Med Res"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/00016489.2013.868604","article-title":"Audiovestibular findings in patients with Vogt-Koyanagi-Harada disease.","volume":"134","author":"Noguchi","year":"2014","journal-title":"Acta Otolaryngol"},{"key":"R39-20250504","first-page":"260","article-title":"Azathioprine reduces the risk of audiometric relapse in immune-mediated hearing loss.","volume":"69","author":"Nieves","year":"2018","journal-title":"Acta Otorrinolaringol Esp"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.otorri.2017.08.004","article-title":"Analysis of audiometric relapse-free survival in patients with immune-mediated hearing loss exclusively treated with corticosteroids.","volume":"69","author":"Mata-Castro","year":"2018","journal-title":"Acta Otorrinolaringol Esp (Engl Ed)"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.290.14.1875","article-title":"Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial.","volume":"290","author":"Harris","year":"2003","journal-title":"JAMA"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/00005537-200209000-00019","article-title":"Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation.","volume":"112","author":"Satoh","year":"2002","journal-title":"Laryngoscope"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00129492-200301000-00012","article-title":"Blockage of immune-mediated inner ear damage by etanercept.","volume":"24","author":"Wang","year":"2003","journal-title":"Otol Neurotol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00405-006-0027-9","article-title":"TNF-alpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.","volume":"263","author":"Lobo","year":"2006","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/01.mao.0000185081.28598.5c","article-title":"Serial audiometry in a clinical trial of AIED treatment.","volume":"26","author":"Niparko","year":"2005","journal-title":"Otol Neurotol"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/archotol.131.8.665","article-title":"Corticosteroid response and supporting cell antibody in autoimmune hearing loss.","volume":"131","author":"Zeitoun","year":"2005","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R47-20250504","first-page":"1037","article-title":"Methotrexate in the management of immune mediated cochleovesitibular disorders: clinical experience with 53 patients.","volume":"28","author":"Salley","year":"2001","journal-title":"J Rheumatol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000320606","article-title":"A pilot study of rituximab in immune-mediated inner ear disease.","volume":"16","author":"Cohen","year":"2011","journal-title":"Audiol Neurootol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1172\/JCI76503","article-title":"Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease.","volume":"124","author":"Vambutas","year":"2014","journal-title":"J Clin Invest"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00129492-200109000-00010","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study.","volume":"22","author":"Rahman","year":"2001","journal-title":"Otol Neurotol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.21179","article-title":"Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.","volume":"53","author":"Matteson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000095897","article-title":"Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.","volume":"11","author":"Van Wijk","year":"2006","journal-title":"Audiol Neurootol"},{"key":"R53-20250504","first-page":"572","article-title":"Plasmapheresis in autoimmune inner ear disease: long-term follow-up.","volume":"18","author":"Luetje","year":"1997","journal-title":"Am J Otol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:06:27Z","timestamp":1746324387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":52,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033889","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}